A Phase II Trial of STI-571/Imatinib (Gleevec (R)) (NSC-716051) in Neuroendocrine Carcinoma of the Skin (Merkel Cell Carcinoma)

Trial Profile

A Phase II Trial of STI-571/Imatinib (Gleevec (R)) (NSC-716051) in Neuroendocrine Carcinoma of the Skin (Merkel Cell Carcinoma)

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2013

At a glance

  • Drugs Imatinib (Primary)
  • Indications Merkel cell carcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Jan 2012 Actual patient number (23) added as reported by ClinicalTrials.gov.
    • 12 Jan 2012 Actual end date (1 Oct 2010) added as reported by ClinicalTrials.gov.
    • 12 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top